AbbVie (ABBV) shares recently declined 1.27%, underperforming a rising market, though the stock has gained 5.95% over the past month. Ahead of its October 2025 earnings report, the company is projected to post a 9.33% year-over-year EPS decline to $2.72, despite an anticipated 7.81% revenue increase to $15.59 billion. Analyst sentiment has seen a 9.65% downward revision in the Zacks Consensus EPS estimate over the last month, resulting in a Zacks Rank #3 (Hold) and a Forward P/E of 19.86, which is at a premium to its industry average.
AbbVie (ABBV) shares experienced a 1.27% decline in the most recent trading session, underperforming the S&P 500's 0.4% gain. Despite this daily dip, the stock has demonstrated strong momentum over the past month, appreciating 5.95% and significantly outperforming both the Medical sector's 1.8% gain and the S&P 500's 1.02% rise. This suggests a recent pullback within a broader positive trend. The upcoming Q4 2025 earnings report projects a 9.33% year-over-year decline in EPS to $2.72, contrasting with an anticipated 7.81% revenue increase to $15.59 billion. For the full fiscal year, EPS is expected to grow 14.03% to $11.54, alongside a 7.72% revenue increase to $60.68 billion. Notably, the Zacks Consensus EPS estimate for ABBV has seen a 9.65% downward revision over the past month, leading to a current Zacks Rank #3 (Hold). AbbVie currently trades at a Forward P/E of 19.86, representing a premium compared to its industry's average of 14.43. However, its PEG ratio of 1.4 is slightly below the Large Cap Pharmaceuticals industry average of 1.6, suggesting a more favorable valuation when accounting for expected earnings growth. The Large Cap Pharmaceuticals industry itself holds a strong Zacks Industry Rank of 97, placing it in the top 40% of all industries.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.15
Ticker Sentiment
